Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.
Allison Angell, the first person in the UK to have all of her major organs transplanted, has died aged 46—more than a decade ...
GlobalData on MSN7d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback